WALTHAM, Mass.– Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent to combine its Pin-point base editing platform with Profluent’s novel AI-engineered proteins. The partnership aims to simplify access for customers to a therapeutically relevant base editing toolkit that enhances precision, safety, and efficiency in gene editing.
The new configuration enables more accurate edits, including single-nucleotide changes without bystander effects. Revvity’s Pin-point platform, designed with modularity in mind, delivers ultra-low amounts of deaminase while maintaining clinically relevant editing levels and reducing off-target activity. This approach offers improved safety and reproducibility for therapeutic applications.
“The advantage of the Pin-point platform is its modularity that allows an exchange of base editing components to enable customers to find their optimal fit-for-purpose design. Our collaboration with Profluent is the first step towards our ultimate aim of offering a toolbox of therapeutically relevant base editing systems,” said Dr. Michelle Fraser, head of cell and gene therapy at Revvity. “Until now, adenine base editors have been limited by traditional protein engineering approaches. Together with Profluent, we’re enabling customers to create next-generation cell and gene therapies using carefully selected components to edit disease-relevant sites, while consciously reducing, and ideally eliminating, the risk of unintended edits elsewhere in the genome.”
Profluent’s AI-driven platform designs proteins from scratch, avoiding the limitations and licensing restrictions of naturally occurring enzymes. When combined with Revvity’s Pin-point system, researchers gain a customizable toolkit capable of accelerating therapeutic development with greater control and precision.
This collaboration builds on earlier research demonstrating the replacement of Cas9 in the Pin-point system with Profluent’s open-access OpenCRISPR nuclease, as published in Nature. By bundling licensing for both the Pin-point platform and Profluent’s adenine deaminases, Revvity seeks to expand the number of disease-related mutations that can be addressed and speed adoption among therapeutic developers.
The joint effort underscores Revvity and Profluent’s shared mission to democratize access to next-generation base editing technologies and advance life-changing therapies for patients worldwide.
